FY2027 EPS Estimates for Novartis Raised by Erste Group Bank

Novartis AG (NYSE:NVS) – Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for Novartis in a research note issued on Friday, September 18th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $9.81 per share for the year, up from their prior forecast of $9.80. The consensus estimate for Novartis’ current full-year earnings is $8.87 per share.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The business had revenue of $14.95 billion for the quarter.

NVS has been the subject of several other research reports. HSBC raised shares of Novartis from a “reduce” rating to a “hold” rating and increased their target price for the stock from $123.00 to $136.00 in a research note on Thursday, September 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft lowered Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 8th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Finally, Royal Bank Of Canada assumed coverage on Novartis in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. Six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $153.00.

Novartis Price Performance

NYSE:NVS opened at $141.20 on Wednesday. The stock has a 50 day moving average of $152.19 and a two-hundred day moving average of $151.62. The firm has a market cap of $269.43 billion, a P/E ratio of 21.30, a price-to-earnings-growth ratio of 2.72 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis has a 12 month low of $121.57 and a 12 month high of $170.46.

Institutional Trading of Novartis

A number of hedge funds and other institutional investors have recently modified their holdings of NVS. Bank of America Corp DE increased its stake in Novartis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after purchasing an additional 413,778 shares in the last quarter. Auto Owners Insurance Co lifted its position in Novartis by 13,687.0% during the 4th quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after acquiring an additional 4,594,726 shares during the last quarter. Franklin Resources Inc. boosted its stake in Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock valued at $617,562,000 after purchasing an additional 419,988 shares during the period. Janus Henderson Group PLC raised its stake in Novartis by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock valued at $347,649,000 after purchasing an additional 41,520 shares during the last quarter. Finally, Cullen Capital Management LLC grew its holdings in shares of Novartis by 0.5% during the 4th quarter. Cullen Capital Management LLC now owns 2,080,796 shares of the company’s stock worth $286,879,000 after purchasing an additional 10,419 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.